On the other hand, the incidence of TP53 mutations showed a statistically significant difference (P < 0.01) between KRAS G12 mutated CRC (64.5%, 143/240) and KRAS wild-type CRC (83.1%, 324/390). This evidence concerns the gene KRAS and colorectal carcinoma.